GeneDx Holdings Corp. (WGS)

GeneDx’s second fiscal quarter of 2026 featured revenue that topped consensus, as results reported August 3, 2026 showed revenue of $114.4 million against a $111.0 million estimate (+3.1%), rising 11.4% year over year from $102.7 million. Gross profit came in at roughly $78.2 million, translating to a gross margin of about 68%, while operating results remained negative with operating income of -$17.5 million and an operating margin of around -15%. The quarter ended with net income of -$17.7 million, down from $10.8 million a year ago, and cash generation was also negative, with operating cash flow of -$29.0 million. For the next period, consensus calls for EPS of $0.07 on revenue of $123.0 million.